SciSparc Ltd.
SciSparc is an Israeli clinical-stage pharmaceutical development company operating through its subsidiary NeuroThera. It focuses on cannabinoid-based technologies and assets, with drug candidates SCI-110, based on THC and CannAmide™, for Tourette syndrome and Alzheimer’s disease agitation, and SCI-210, based on CBD and CannAmide™, for autism spectrum disorder and status epilepticus. SCI-110 and SCI-210 are being studied in clinical or preclinical programs; SciSparc is not actively advancing SCI-210 for status epilepticus. CannAmide™ also has a Health Canada product license as an oral tablet recommended for anti-inflammatory use and chronic pain relief. A majority-owned subsidiary sells hemp seed oil-based and other products on Amazon Marketplace. SciSparc is headquartered in Tel Aviv, Israel.
No SEC Form 4 filings for $SPRC in the last 30 days.
See all $SPRC insider activity →SciSparc Ltd. (SPRC) announced a strategic shift to focus on Agentic AI technologies, particularly in cybersecurity and finance. The company plans to evaluate opportunities in these markets, building on its scientific foundation. SciSparc currently operates in pharmaceutical development through its subsidiary NeuroThera.
SciSparc Ltd. (SPRC) stock surged 39.44% on October 26, 2026, driven by positive sentiment around its Tourette syndrome drug trial and AI initiatives. The company's subsidiary, NeuroThera Labs, advanced its drug candidate SCI-110 into a Phase IIb trial, while its AI division, CliniQuantum, demonstrated significant performance improvements. SPRC trades at a fraction of its book value, reflecting both skepticism and potential value if its pipeline or AI initiatives gain traction.
SciSparc's subsidiary NeuroThera completed manufacturing and received European QP batch release for SCI-110, allowing site activation and near-term patient enrollment in its FDA-approved Phase IIb Tourette syndrome trial, according to the company.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning SPRC (SciSparc Ltd.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent SPRC coverage spans financial news, market movers and technology.
The announcement is a forward‑looking strategic pivot with no immediate revenue or deal details.
The Phase IIb start de‑risks the biotech pipeline and could trigger a short squeeze if enrollment proceeds as expected.
The batch release removes a manufacturing bottleneck and moves the trial toward patient enrollment, which could drive short‑term upside if enrollment begins as expected.
Positive regulatory progress may lift SciSparc's stock as the trial moves toward patient enrollment.
The announcement sparked strong buying pressure on SPRC.
AlphAI scores every news story that mentions SPRC with an AI model for sentiment and relevance, and aggregates insider trades from SciSparc Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SciSparc Ltd. (SPRC) announced a strategic shift to focus on Agentic AI technologies, particularly in cybersecurity and finance. The company plans to evaluate opportunities in these markets, building on its scientific foundation. SciSparc currently operates in pharmaceutical development through its subsidiary NeuroThera.
1 min readSciSparc Ltd. (SPRC) stock surged 39.44% on October 26, 2026, driven by positive sentiment around its Tourette syndrome drug trial and AI initiatives. The company's subsidiary, NeuroThera Labs, advanced its drug candidate SCI-110 into a Phase IIb trial, while its AI division, CliniQuantum, demonstrated significant performance improvements. SPRC trades at a fraction of its book value, reflecting both skepticism and potential value if its pipeline or AI initiatives gain traction.
2 min readSciSparc's subsidiary NeuroThera completed manufacturing and received European QP batch release for SCI-110, allowing site activation and near-term patient enrollment in its FDA-approved Phase IIb Tourette syndrome trial, according to the company.
1 min readSciSparc (Nasdaq: SPRC) announced that its subsidiary, NeuroThera Labs (TSXV: NTLX), has completed manufacturing and obtained regulatory approval for its Phase IIb clinical trial of SCI-110, a drug for Tourette Syndrome. The trial will be conducted at three sites, including Yale and Tel Aviv Sourasky Medical Center. SCI-110 combines dronabinol and PEA, aiming to address unmet treatment needs for TS. Patient enrollment is expected to begin soon, marking a significant milestone for NeuroThera.
2 min readScisparc (SPRC) stock rose 37% in pre-market trading after announcing a strategic shift to AI-powered technologies, focusing on cybersecurity and fintech. The Tel Aviv-based firm, previously a clinical-stage pharmaceutical developer, plans to explore agentic AI opportunities but cautioned no guarantees. The surge contrasts with broader tech selloffs due to inflation fears. No analyst upgrades accompanied the news, with recent ratings being 'hold' and 'sell'.
1 min readChina SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.
3 min readSciSparc (SPRC) announced that its subsidiary NeuroThera's CliniQuantum achieved a 16.8x computational acceleration using quantum-simulation on an S&P 500 company's quantum architecture. The analysis of gene combinations was completed in 0.5 hours with GPU acceleration compared to 8.4 hours with CPU. CliniQuantum plans to advance its algorithms for larger datasets and quantum hardware.
1 min readSciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.
2 min readSciSparc (NASDAQ:SPRC) shares fell 20.31% to $6.93 in premarket trading, as broader markets were slightly higher. The company said its subsidiary NeuroThera Labs completed internal validation of a quantum sampling workflow for clinical analytics and began a Phase IIb trial site at Hannover Medical School for SCI-110, a cannabinoid treatment for adult Tourette syndrome.
3 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min read
